Lipoprotein Apheresis for Lipoprotein(a) and Cardiovascular Disease

Elevated lipoprotein(a) (Lp(a)) is an independent risk factor for cardiovascular disease (CVD). In the United States (US), lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany utilizes LA therapy for patients with an Lp(a)> 60 mg/dL, normal LDL-C levels, and CVD. LA therapy in this population demonstrated a> 70% reduction in CVD events. In the US, LA is only approved for patients with elevated LDL-C levels, regardless of Lp(a) level.
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research